Simulations of Absorption, Metabolism, and Bioavailability

Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability

Volumn 40, Issue , 2009, Pages 453-495

  Bolger, Michael B ^a   Fraczkiewicz, Robert ^a   Lukacova, Viera ^a  

^a NONE   (United States)

Author keywords

Apparent permeability; Compartmental absorption and transit model; Pharmacokinetics; Physiologically based pharmacokinetics; Transcellular epithelial electrical resistance

Indexed keywords

PHARMACOKINETICS; PHYSIOLOGICAL MODELS;

APPARENT PERMEABILITIES; ELECTRICAL RESISTANCES;

BIOCHEMISTRY;

EID: 84865714445     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623860.ch17     Document Type: Chapter

References (155)

1. Modi, S. (2003) Computational approaches to the understanding of ADMET properties and problems. Drug Discovery Today, 8 (14), 621-623.
2. van de Waterbeemd, H. and Gifford, E. (2003) ADMET in silico modelling: towards prediction paradise? Nature Reviews. Drug Discovery, 2 (3), 192-204.
3. Stoner, C.L., Gifford, E., Stankovic, C., Lepsy, C.S., Brodfuehrer, J., Prasad, J.V. and Surendran, N. (2004) Implementation of an ADME enabling selection and visualization tool for drug discovery. Journal of Pharmaceutical Sciences, 93 (5), 1131-1141.
4. Yamashita, F. and Hashida, M. (2004) In silico approaches for predicting ADME properties ofdrugs. Drug Metabolism and Pharmacokinetics, 19 (5), 327-338.
5. Balakin, K.V., Ivanenkov, Y.A., Savchuk, N.P., Ivashchenko, A.A. and Ekins, S. (2005) Comprehensive computational assessment of ADME properties using mapping techniques. Current Drug Discovery Technologies, 2 (2), 99-113.
6. Lupfert, C. and Reichel, A. (2005) Development and application of physiologically based pharmacokinetic modeling tools to support drug discovery. Chemistry & Biodiversity, 2 (11), 1462-1486.
7. Cai, H., Stoner, C., Reddy, A., Freiwald, S., Smith, D., Winters, R., Stankovic, C. and Surendran, N. (2006) Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. International Journal of Pharmaceutics, 308 (1-2), 133-139.
8. Jones, H.M., Parrott, N., Jorga, K. and Lave, T. (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clinical Pharmacokinetics, 45 (5), 511-542.
9. Jones, H.M., Parrott, N., Ohlenbusch, G. and Lave, T. (2006) Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clinical Pharmacokinetics, 45 (12), 1213-1226.
10. De Buck, S.S., Sinha, V.K., Fenu, L.A., Gilissen, R.A., Mackie, C.E. and Nijsen, M.J. (2007) The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism based absorption, distribution, and metabolism prediction tools. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (4), 649-659.
11. De Buck, S.S., Sinha, V.K., Fenu, L.A., Nijsen, M.J., Mackie, C.E. and Gilissen, R.A. (2007) Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (10), 1766-1780.
12. Rowland, M., Balant, L. and Peck, C. (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPSJournal, 6 (1), E6.
13. Bolger, M.B., Fraczkiewicz, R. and Steere, B. (2006) In silico surrogates for vivo properties: profiling for ADME and toxicological behaviour, in Exploiting Chemical Diversity for Drug Discovery (eds P.A. Bartlett and M. Entzeroth), Royal Society of Chemistry, London, pp. 364-381.
14. Bolger, M.B., Fraczkiewicz, R., Entzeroth, M. and Steere, B. (2006) Concepts for in vitro profiling: Drug activity, selectivity, and liability, in Exploiting Chemical Diversity for Drug Discovery (eds P.A. Bartlett and M. Entzeroth), Royal Society of Chemistry, London, pp. 336-362.
15. Jolivette, L.J. and Ekins, S. (2007) Methods for predicting human drug metabolism. Advances in Clinical Chemistry, 43, 131-176.
16. Haworth, I.S. (2006) Computational drug delivery. Advanced Drug Delivery Reviews, 58 (12-13), 1271-1273.
17. Ekins, S., Nikolsky, Y. and Nikolskaya, T. (2005) Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends in Pharmacological Sciences, 26 (4), 202-209.
18. Ekins, S. (2006) Systems-ADME/Tox: resources and network approaches. Journal ofPharmacological and Toxicological Methods, 53 (1), 38-66.
19. Powell, J.R. and Gobburu, J.V. (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clinical Pharmacology and Therapeutics, 82 (1), 97-102.
20. Lalonde, R.L., Kowalski, K.G., Hutmacher, M.M., Ewy, W., Nichols, D.J., Milligan, P.A., Corrigan, B.W., Lockwood, P.A., Marshall, S.A., Benincosa, L.J., Tensfeldt, T.G., Parivar, K., Amantea, M., Glue, P., Koide, H. and Miller, R. (2007) Model-based drug development. Clinical Pharmacology and Therapeutics, 82 (1), 21-32.
21. Zhang, L., Sinha, V., Forgue, S.T., Callies, S., Ni, L., Peck, R. and Allerheiligen, S.R. (2006) Model-based drug development: the road to quantitative pharmacology. Journal of Pharmacokinetics and Pharmacodynamics, 33 (3), 369-393.
22. Miller, R., Ewy, W., Corrigan, B.W., Ouellet, D., Hermann, D., Kowalski, K.G., Lockwood, P., Koup, J.R., Donevan, S., El-Kattan, A., Li, C.S., Werth, J.L., Feltner, D.E. and Lalonde, R.L. (2005) How modeling and simulation have enhanced decision making in new drug development. Journal of Pharmacokinetics and Pharmacodynamics, 32 (2), 185-197.
23. Hall, S.D., Thummel, K.E., Watkins, P.B., Lown, K.S., Benet, L.Z., Paine, M.F., Mayo, R.R., Turgeon, D.K., Bailey, D.G., Fontana, R.J. and Wrighton, S.A. (1999) Molecular and physical mechanisms of first-pass extraction. DrugMetabolism and Disposition: The Biological Fate of Chemicals, 27 (2), 161-166.
24. Yu, L.X., Lipka, E., Crison, J.R. and Amidon, G.L. (1996) Transport approaches to the biopharmaceutical design of oral drug delivery system: prediction of intestinal absorption. Advanced Drug Delivery Reviews, 19, 359-376.
25. Jacobs, M.H. (1940) Some aspects of cell permeability to weak electrolytes. Cold Spring Harbor Symposia on Quantitative Biology, 8, 30-39.
26. Hogben, C.A.M.,Tocco, D.J., Brodie, B.B. and Schanker, L.S. (1959) On the mechanism of intestinal absorption of drugs. The Journal ofPharmacology and Experimental Therapeutics, 125, 275-282.
27. Palm, K., Luthman, K., Ros, J., Grasjo, J. and Artursson, P. (1999) Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs. The Journal of Pharmacology and Experimental Therapeutics, 291 (2), 435-443.
28. Suzuki, A., Higuchi, W.I. and Ho, N.F. (1970) Theoretical model studies of drug absorption and transport in the gastrointestinal tract. 2. Journal of Pharmaceutical Sciences, 59 (5), 651-659.
29. Suzuki, A., Higuchi, W.I. and Ho, N.F. (1970) Theoretical model studies of drug absorption and transport in the gastrointestinal tract.1. Journal of Pharmaceutical Sciences, 59 (5), 644-651.
30. Ho, N.F., Higuchi, W.I. andTuri, J. (1972) Theoretical model studies of drug absorptionandtransportinthe GI tract. 3. Journal of Pharmaceutical Sciences, 61 (2), 192-197.
31. Ho, N.F. and Higuchi, W.I. (1971) Quantitative interpretation of in vivo buccal absorption of n-alkanoic acids by the physical model approach. Journal of Pharmaceutical Sciences, 60 (4), 537-541.
32. Dressman, J.B., Fleisher, D. and Amidon, G.L. (1984) Physicochemical model for dose-dependent drug absorption. Journal of Pharmaceutical Sciences, 73 (9), 127-1279.
33. Suttle, A.B., Pollack, G.M. and Brouwer, K.L. (1992) Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharmaceutical Research, 9 (3), 350-356.
34. Wright, J.D., Ma, T., Chu, C.K. and Boudinot, F.D. (1996) Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl beta-L-arabinofuranosyl)uracil (L-FMAU) in rats. Biopharmaceutics & Drug Disposition, 17 (3), 197-207.
35. Grass, G.M. (1997) Simulation models to predict oral drug absorption from in vitro data. Advanced Drug Delivery Reviews, 23, 199-219.
36. Norris, D.A., Leesman, G.D., Sinko, P.J. and Grass, G.M. (2000) Development of predictive pharmacokinetic simulation models for drug discovery. Journal of Controlled Release, 65 (1-2), 55-62.
37. Cong, D., Doherty, M. and Pang, K.S. (2000) A new physiologically based, segregated-f model to explain route dependent intestinal metabolism. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 28 (2), 22-235.
38. Kalampokis, A., Argyrakis, P. and Macheras, P. (1999) A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. Pharmaceutical Research, 16 (11), 176-1769.
39. Kalampokis, A., Argyrakis, P. and Macheras, P. (1999) Heterogeneous tube model for the study of small intestinal transit flow. Pharmaceutical Research, 16 (1), 87-91.
40. Ito, K., Kusuhara, H. and Sugiyama, Y. (1999) Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharmaceutical Research, 16 (2), 225-231.
41. Rostami-Hodjegan, A. and Tucker, G.T. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews. Drug Discovery, 6 (2), 140-148.
42. Willmann, S., Schmitt, W., Keldenich, J. and Dressman, J.B. (2003) A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharmaceutical Research, 20 (11), 1766-1771.
43. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J. and Dressman, J.B. (2004) A physiological model for the estimation of the fraction dose absorbed in humans. Journal of Medicinal Chemistry, 47 (16), 4022-4031.
44. Agoram, B., Woltosz, W.S. and Bolger, M.B. (2001) Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Advanced Drug Delivery Reviews, 50 (Suppl. 1) S41-S67.
45. Aarons, L., Karlsson, M.O., Mentre, F., Rombout, F., Steimer, J.L. and van Peer, A. (2001) Role of modelling and simulation in phase I drug development. European Journal of Pharmaceutical Sciences, 13 (2), 115-122.
46. Yu, L.X. and Amidon, G.L. (1999) A compartmental absorption and transit model for estimating oral drug absorption. International Journal of Pharmaceutics, 186 (2), 119-125.
47. Lipinski, C.A., Lombardo, F., Dominy, B. W. and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 23 (1-3), 3-25.
48. Andrews, C.W., Bennett, L. and Yu, L.X. (2000) Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship Pharmaceutical Research, 17 (6), 639-644.
49. Oprea, T.I. and Gottfries, J. (1999) Toward minimalistic modeling of oral drug absorption. Journal ofMolecular Graphics & Modelling, 17 (5-6), 261-274, 329.
50. Stenberg, P., Luthman, K., Ellens, H., Lee, C.P., Smith, P.L., Lago, A., Elliott, J.D. and Artursson, P. (1999) Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharmaceutical Research, 16 (10), 1520-1526.
51. Matter, H., Baringhaus, K.H., Naumann, T., Klabunde, T. and Pirard, B. (2001) Computational approaches towards the rational design of drug-like compound libraries. Combinatorial Chemistry & High Throughput Screening, 4 (6), 453-475.
52. Osterberg, T. and Norinder, U. (2000) Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. Journal of Chemical Information and Computer Sciences, 40 (6), 1408-1411.
53. Chiou, W.L. and Barve, A. (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharmaceutical Research, 15 (11), 1792-1795.
54. Zhao, Y.H., Le, J., Abraham, M.H., Hersey, A., Eddershaw, P.J., Luscombe, C.N., Butina, D., Beck, G., Sherborne, B., Cooper, I., Platts, J.A. and Boutina, D. (2001) Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. Journal of Pharmaceutical Sciences, 90 (6), 749-784.
55. Matthews, E.J., Kruhlak, N.L., Benz, R.D. and Contrera, J.F. (2004) Assessment of the health effects ofchemicals in humans:I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Current Drug Discovery Technologies, 1 (1), 61-76.
56. Russom, C.L., Bradbury, S.P., Broderius, S.J., Hammermeister, D.E. and Drummond, R.A. (1997) Predicting modes of toxic action from chemical structure: acute toxicity in the fathead minnow (Pimephales promelas). Environmental Toxicology and Chemistry/ SETAC, 16 (5), 948-967.
57. Gold, L.S., Manley, N.B., Slone, T.H. and Rohrbach, L. (1999) Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. Environmental Health Perspectives, 107 (Suppl. 4) 527-600.
58. Bains, W., Basman, A. and White, C. (2004) HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Progress in Biophysics and Molecular Biology, 86 (2), 205-233.
59. Keseru, G.M. (2003) Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorganic & Medicinal Chemistry Letters, 13 (16), 2773-2775.
60. Cohen, S.D. and Hindmarsh, A.C. (1996) CVODE, a stiff/nonstiffODE solver in C. Computers in Physics, 10 (2), 138-143.
61. Pade, V. and Stavchansky, S. (1997) Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharmaceutical Research, 14 (9), 1210-1215.
62. Ungell, A.L., Nylander, S., Bergstrand, S., Sjoberg, A. and Lennernas, H. (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. Journal of Pharmaceutical Sciences, 87 (3), 360-366.
63. Adson, A., Burton, P.S., Raub, T.J., Barsuhn, C.L., Audus, K.L. and Ho, N.F. (1995) Passive diffusion ofweak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. Journal ofPharmaceutical Sciences, 84 (10), 1197-1204.
64. Fordtran, J.S., Rector, F.C., Jr. Ewton, M.F., Soter, N. and Kinney, J. (1965) Permeability characteristics of the human small intestine. The Journal of Clinical Investigation, 44 (12), 1935-1944.
65. Soergel, K.H., Whalen, G.E. and Harris, J.A. (1968) Passive movement of water and sodium across the human small intestinal mucosa. Journal ofApplied Physiology, 24 (1), 40-48.
66. Artursson, P. and Karlsson, J. (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications, 175 (3), 880-885.
67. Billich, C.O. and Levitan, R. (1969) Effects of sodium concentration and osmolality on water and electrolyte absorption form the intact human colon. The Journal of Clinical Investigation, 48 (7), 1336-1347.
68. Maruyama, W., Yoshida, K., Tanaka, T. and Nakanishi, J. (2002) Determination of tissue-blood partition coefficients for a physiological model for humans, and estimation of dioxin concentration in tissues. Chemosphere, 46 (7), 975-985.
69. Sarangapani, R., Teeguarden, J.G., Cruzan, G., Clewell, H.J. and Andersen, M.E. (2002) Physiologically based pharmacokinetic modeling ofstyrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhalation Toxicology, 14 (8), 789-834.
70. Thrall, K.D., Soelberg, J.J., Weitz, K.K. andWoodstock,A.D. (2002) Development of a physiologically based pharmacokinetic model for methyl ethyl ketone in F344 rats. Journal of Toxicology and Environmental Health. Part A, 65 (13), 881-896.
71. Nestorov, I.A., Aarons, L.J. and Rowland, M. (1997) Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis. Journal of Pharmacokinetics and Biopharmaceutics, 25 (4), 413-447.
72. Kawai, R., Lemaire, M., Steimer, J.L., Bruelisauer, A., Niederberger, W. and Rowland, M. (1994) Physiologicallybased pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. Journal of Pharmacokinetics and Biopharmaceuticst, 22 (5), 327-365.
73. Bjorkman, S., Wada, D.R., Berling, B.M. and Benoni, G. (2001) Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. Journal of Pharmaceutical Sciences, 90 (9), 1226-1241.
74. Fouchecourt, M.O., Beliveau, M. and Krishnan, K. (2001) Quantitative structure-pharmacokinetic relationship modelling. The Science of the Total Environment, 274 (1-3), 125-135.
75. Pelekis, M., Poulin, P. and Krishnan, K. (1995) An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. Toxicology and Industrial Health, 11 (5), 511-522.
76. Payne, M.P. and Kenny, L.C. (2002) Comparison ofmodels for the estimation ofbiological partition coefficients. Journal of Toxicology and Environmental Health. Part A, 65 (13), 897-931.
77. Poulin, P. and Theil, F.P. (2000) Apriori prediction of tissue:plasma partition coefficients ofdrugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. Journal of Pharmaceutical Sciences, 89 (1), 16-35.
78. Luttringer, O., Theil, F.P., Poulin, P., Schmitt-Hoffmann, A.H., Guentert, T.W. and Lave, T. (2003) Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. Journal ofPharmaceutical Sciences, 92 (10), 1990-2007.
79. Theil, F.P., Guentert, T.W., Haddad, S. and Poulin, P. (2003) Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicology Letters, 138 (1-2), 29-39.
80. Poulin, P. and Theil, F.P. (2002) Prediction ofpharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. Journal of Pharmaceutical Sciences, 91 (5), 1358-1370.
81. De Buck, S.S. and Mackie, C.E. (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opinion on Drug Metabolism and Toxicology, 3 (6), 865-878.
82. Rodgers, T., Leahy, D. and Rowland, M. (2005) Tissue distribution ofbasic drugs: accounting for enantiomeric, compound and regional differences amongst betablocking drugs in rat. Journal of Pharmaceutical Sciences, 94 (6), 1237-1248.
83. Rodgers, T., Leahy, D. and Rowland, M. (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to strong bases. Journal of Pharmaceutical Sciences, 94 (6), 1259-1276.
84. Rodgers, T. and Rowland, M. (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. Journal of Pharmaceutical Sciences, 95 (6), 1238-1257.
85. Rodgers, T. and Rowland, M. (2007) Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharmaceutical Research, 24 (5), 918-933.
86. Brightman, F.A., Leahy, D.E., Searle, G.E. and Thomas, S. (2006) Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34 (1), 84-93.
87. Willmann, S., Hohn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W., Lippert, J. and Schmitt, W. (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal ofPharmacokinetics and Pharmacodynamics, 34 (3), 401-431.
88. Paine, M.F., Khalighi, M., Fisher, J.M., Shen, D.D., Kunze, K.L., Marsh, C.L., Perkins, J.D. and Thummel, K.E. (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. The Journal ofPharmacology and Experimental Therapeutics, 283 (3), 1552-1562.
89. Madani, S., Paine, M.F., Lewis, L., Thummel, K.E. and Shen, D.D. (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharmaceutical Research, 16 (8), 1199-1205.
90. Bornemann, L.D., Min, B.H., Crews, T., Rees, M.M., Blumenthal, H.P., Colburn, W.A. and Patel, I.H. (1985) Dose dependent pharmacokinetics of midazolam. European Journal of Clinical Pharmacology, 29 (1), 91-95.
91. Kupferschmidt, H.H., Fattinger, K.E., Ha, H.R., Follath, F. and Krahenbuhl, S. (1998) Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. British Journal of Clinical Pharmacology, 45 (4), 355-359.
92. Gupta, S.K. and Sathyan, G. (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate release oxybutynin. Journal of Clinical Pharmacology, 39 (3), 289-296.
93. Korolev, D., Balakin, K.V., Nikolsky, Y., Kirillov, E., Ivanenkov, Y.A., Savchuk, N.P., Ivashchenko, A.A. and Nikolskaya, T. (2003) Modelingofhumancytochrome p450-mediated drug metabolism using unsupervised machine learning approach. Journal ofMedicinal Chemistry, 46 (17), 3631-3643.
94. Balakin, K.V., Ekins, S., Bugrim, A., Ivanenkov, Y.A., Korolev, D., Nikolsky, Y.V., Skorenko, A.V., Ivashchenko, A.A., Savchuk, N.P. and Nikolskaya, T. (2004) Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 32 (10), 1183-1189.
95. Korzekwa, K.R., Jones, J.P. and Gillette, J.R. (1990) Theoretical studies on cytochrome P-450 mediated hydroxylation: a predictive model for hydrogen atom abstractions. Journal ofthe American Chemical Society, 112, 7042-7046.
96. Korzekwa, K.R., Trager, W.F., Mancewicz, J. and Osawa, Y. (1993) Studies on the mechanism of aromatase and other cytochrome P450 mediated deformylation reactions. The Journal of Steroid Biochemistry and Molecular Biology, 44 (4-6), 367-373.
97. Korzekwa, K.R. and Jones, J.P. (1993) Predicting the cytochrome P450mediated metabolism ofxenobiotics. Pharmacogenetics, 3 (1), 1-18.
98. Jones, J.P. and Korzekwa, K.R. (1996) Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. Methods in Enzymology, 272, 326-335.
99. Jones, J.P., Mysinger, M. and Korzekwa, K. R. (2002) Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 30 (1), 7-12.
100. Singh, S.B., Shen, L.Q., Walker, M.J. and Sheridan, R.P. (2003) A model for predicting likely sites of CYP3A4 mediated metabolism on drug-like molecules. Journal ofMedicinal Chemistry, 46 (8), 1330-1306.
101. Sheridan, R.P., Korzekwa, K.R., Torres, R.A. and Walker, M.J. (2007) Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. Journal ofMedicinal Chemistry, 50 (14), 3173-3184.
102. de Groot, M.J., Vermeulen, N.P., Kramer, J.D., van Acker, F.A. and Donne-Op den Kelder, G.M. (1996) A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures ofP450 101, P450 102, and P450 108. Chemical Research in Toxicology, 9 (7), 1079-1091.
103. de Groot, M.J., Alex, A.A. and Jones, B.C. (2002) Development of a combined protein and pharmacophore model for cytochrome P450 2C9. Journal of Medicinal Chemistry, 45 (10), 1983-1993.
104. de Groot, M.J., Kirton, S.B. and Sutcliffe, M.J. (2004) In silico methods for predicting ligand binding determinants of cytochromes P450. Current Topics in Medicinal Chemistry, 4 (16), 1803-1824.
105. de Groot, M.J. (2006) Designing better drugs: predicting cytochrome P450 metabolism. Drug Discovery Today, 11 (13-14), 601-606.
106. Cruciani, G., Carosati, E., De Boeck, B., Ethirajulu, K., Mackie, C., Howe, T. and Vianello, R. (2005) MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. Journal ofMedicinal Chemistry, 48 (22), 6970-6979.
107. Zamora, I., Afzelius, L. and Cruciani, G. (2003) Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. Journal ofMedicinal Chemistry, 46 (12), 2313-2324.
108. O'Neill, R.T. (2006) FDA's critical path initiative: a perspective on contributions ofbiostatistics. Biometrical Journal, 48 (4), 559-564.
109. Woosley, R.L. and Cossman, J. (2007) Drug development and the FDA's critical path initiative. Clinical Pharmacology and Therapeutics, 81 (1), 129-133.
110. Woodcock, J. and Woosley, R. (2008) The FDA critical path initiative and its influence on new drug development. Annual Review of Medicine, 59, 1-12.
111. Leonce, S., Pierre, A., Anstett, M., Perez, V., Genton, A., Bizzari, J.P. andAtassi, G. (1992) Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein mediated multidrug resistance. Biochemical Pharmacology, 44 (9), 1707-1715.
112. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.P. and Kirchgessner, T.G. (1999) A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. The Journal of Biological Chemistry, 274 (52), 37161-37168.
113. Chen, C., Lin, J., Smolarek, T. and Tremaine, L. (2007) P-Glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (10), 1725-1729.
114. Holtzman, C.W., Wiggins, B.S. and Spinler, S.A. (2006) RoleofP-glycoprotein in statin drug interactions. Pharmacotherapy, 26 (11), 1601-1607.
115. de Koning, H.P. and Jarvis, S.M. (1997) Hypoxanthine uptake through a purine selective nucleobase transporter in Trypanosoma brucei brucei procyclic cells is driven by protonmotive force. European Journal ofBiochemistry, 247 (3), 1102-1110.
116. Balch, W.E. andWolfe, R.S. (1979) Transport of coenzyme M (2 mercaptoethanesulfonic acid) in methanobacterium ruminantium. Journal of Bacteriology, 137 (1), 264-273.
117. Shima, Y., Maeda, T., Aizawa, S., Tsuboi, I., Kobayashi, D., Kato, R. and Tamai, I. (2006) L-arginine import via cationic amino acid transporter CAT1 is essential for both differentiation and proliferation of erythrocytes. Blood, 107 (4), 1352-1356.
118. Zhou, M., Xia, L. and Wang, J. (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35 (10), 1956-1962.
119. Swaan, P.W. and Tukker, J.J. (1997) Molecular determinants of recognition for the intestinal peptide carrier. Journal of Pharmaceutical Sciences, 86 (5), 596-602.
120. Nagakubo, J., Tomimatsu, T., Kitajima, M., Takayama, H., Aimi, N. and Horie, T. (2001) Characteristics of transport of fluoresceinated methotrexate in rat small intestine. Life Sciences, 69 (7), 739-747.
121. Luckner, P. and Brandsch, M. (2005) Interaction of 31 beta-lactam antibiotics with the H + /peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. European Journal of Pharmaceutics and Biopharmaceutics, 59 (1), 17-24.
122. Katiyar, S.K. and Edlind, T.D. (2001) Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Medical Mycology, 39 (1), 109-116.
123. Chang, C., Bahadduri, P.M., Polli, J.E., Swaan, P.W. and Ekins, S. (2006) Rapid identification ofP-glycoprotein substrates and inhibitors. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 34 (12), 1976-1984.
124. Terao, T., Hisanaga, E., Sai, Y., Tamai, I. and Tsuji, A. (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. The Journal ofPharmacy and Pharmacology, 48 (10), 1083-1089.
125. Honscha, W., Schulz, K., Muller, D. and Petzinger, E. (1993) TwodifferentmRNAs from rat liver code for the transport of bumetanide and taurocholate in Xenopus laevis oocytes. European Journal of Pharmacology, 246 (3), 227-232.
126. Sadoogh-Abasian, F. and Evered, D.F. (1980) Absorption of nicotinic acid and nicotinamide from rat small intestine in vitro. Biochimica et Biophysica Acta, 598 (2), 385-391.
127. Hu, M. and Amidon, G.L. (1988) Passive and carrier-mediated intestinal absorption components of captopril. Journal ofPharmaceutical Sciences, 77 (12), 1007-1011.
128. Nakamura, H., Sano, H., Yamazaki, M. and Sugiyama, Y. (1994) Carrier-mediated active transport ofhistamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: contribution of type I system. The Journal of Pharmacology and Experimental Therapeutics, 269 (3), 1220-1227.
129. de Lange, E.C., Marchand, S., van den Berg, D., van der Sandt, I.C., de Boer, A.G., Delon, A., Bouquet, S. and Couet, W. (2000) In vitro and in vivo investigations on fluoroquinolones; effects of the P glycoprotein efflux transporter on brain distribution of sparfloxacin. European Journal ofPharmaceutical Sciences, 12 (2), 85-93.
130. Swaan, P.W., Stehouwer, M.C. and Tukker, J.J. (1995) Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochimica et Biophysica Acta, 1236 (1), 31-38.
131. Lauterbach, F. (1987) Intestinal permeation of nonquaternary amines: a study with telenzepine and pirenzepine in the isolated mucosa of guinea pig jejunum and colon. The Journal of Pharmacology and Experimental Therapeutics, 243 (3), 1121-1130.
132. Boulton, D.W., DeVane, C.L., Liston, H.L. and Markowitz, J.S. (2002) In vitro P glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 71 (2), 163-169.
133. Covitz, K.M., Amidon, G.L. and Sadee, W. (1996) Human dipeptide transporter, hPEPT1, stably transfected into Chinese hamster ovary cells. Pharmaceutical Research, 13 (11), 1631-1634.
134. Hatanaka, T. (2000) Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clinical Pharmacokinetics, 39 (6), 397-412.
135. Metzner, L., Neubert, K. and Brandsch, M. (2006) Substrate specificity of the amino acid transporter PAT1. Amino Acids, 31 (2), 111-117.
136. Anderson,C.M.andThwaites,D.T. (2005) Indirect regulation of the intestinal H + coupled amino acid transporter hPAT1 (SLC36A1). Journal of Cellular Physiology, 204 (2), 604-613.
137. van Kalken, C.K., Broxterman, H.J., Pinedo, H.M., Feller, N., Dekker, H., Lankelma, J. and Giaccone, G. (1993) Cortisol is transported by the multidrug resistance gene product P-glycoprotein. British Journal of Cancer, 67 (2), 284-289.
138. Yao, H.M. and Chiou, W.L. (2006) The complexity of intestinal absorption and exsorption ofdigoxin in rats. International Journal ofPharmaceutics, 322 (1-2), 79-86.
139. Lau, Y.Y., Wu, C.Y., Okochi, H. and Benet, L.Z. (2004) Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. The Journal ofPharmacology and Experimental Therapeutics, 308 (3), 1040-1045.
140. Makhey, V.D., Guo, A., Norris, D.A., Hu, P., Yan, J. and Sinko, P.J. (1998) Characterization ofthe regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharmaceutical Research, 15 (8), 1160-1167.
141. Swaan, P.W. and Tukker, J.J. (1995) Carrier-mediated transport mechanism of foscarnet (trisodium phosphonoformate hexahydrate) in rat intestinal tissue. The Journal ofPharmacology and Experimental Therapeutics, 272 (1), 242-247.
142. Collett, A., Higgs, N.B., Sims, E., Rowland, M. and Warhurst, G. (1999) Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. The Journal of Pharmacology and Experimental Therapeutics, 288 (1), 171-178.
143. Uchino, H., Kanai, Y., Kim, D.K., Wempe, M.F., Chairoungdua, A., Morimoto, E., Anders, M.W. and Endou, H. (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Molecular Pharmacology, 61 (4), 729-737.
144. Johansson, O., Lindberg, T., Melander, A. and Wahlin-Boll, E. (1985) Different effects of different nutrients on theophylline absorption in man. Drug Nutrient Interactions, 3 (4), 205-211.
145. Metzner, L., Kottra, G., Neubert, K., Daniel, H. and Brandsch, M. (2005) Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB Journal, 19 (11), 1468-1473.
146. Metzner, L. and Brandsch, M. (2006) Influence of a proton gradient on the transport kinetics of the H + /amino acid cotransporter PAT1 in Caco-2 cells. European Journal of Pharmaceutics and Biopharmaceutics, 63 (3), 360-364.
147. Lambie, D.G. and Johnson, R.H. (1985) Drugs and folate metabolism. Drugs, 30 (2), 145-155.
148. Zimmerman, J., Selhub, J. and Rosenberg, I.H. (1987) Competitive inhibition of folate absorption by dihydrofolate reductase inhibitors, trimethoprim and pyrimethamine. The American Journal of Clinical Nutrition, 46 (3), 518-522.
149. Broer, S. (2006) The SLC6 orphans are forming a family of amino acid transporters. Neurochemistry International, 48 (6-7), 559-567.
150. Zhang, L., Li, X.Z. and Poole, K. (2001) Fluoroquinolone susceptibilities of efflux mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. The Journal of Antimicrobial Chemotherapy, 48 (4), 549-552.
151. Uchino, H., Kanai,Y., Kimdo, K.,Wempe, M.F., Chairoungdua, A., Morimoto, E., Anders, M.W. and Endou, H. (2002) Transport of amino acid-related compounds mediated by L-type amino acidtransporter 1 (LAT1): insights intothe mechanisms of substrate recognition. Molecular Pharmacology, 61 (4), 729-737.
152. Saitoh, H. and Aungst, B.J. (1995) Possible involvement of multiple P glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharmaceutical Research, 12 (9), 1304-1310.
153. Ngo, L.Y., Patil, S.D. and Unadkat, J.D. (2001) Ontogenic and longitudinal activity of Na( + )-nucleoside transporters in the human intestine. American Journal of Physiology. Gastrointestinal and Liver Physiology, 280 (3), G475-G481.
154. Wenzel, U., Thwaites, D.T. and Daniel, H. (1995) Stereoselective uptake of beta lactam antibiotics bythe intestinal peptide transporter. British Journal of Pharmacology, 116 (7), 3021-3027.
155. Hu, M., Chen, J., Zhu, Y., Dantzig, A.H., Stratford, R.E., Jr and Kuhfeld, M.T. (1994) Mechanism and kinetics of transcellular transport of a new beta lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Pharmaceutical Research, 11 (10), 1405-1413.